[go: up one dir, main page]

MX2017000527A - Formulaciones de anticuerpos cristalinos. - Google Patents

Formulaciones de anticuerpos cristalinos.

Info

Publication number
MX2017000527A
MX2017000527A MX2017000527A MX2017000527A MX2017000527A MX 2017000527 A MX2017000527 A MX 2017000527A MX 2017000527 A MX2017000527 A MX 2017000527A MX 2017000527 A MX2017000527 A MX 2017000527A MX 2017000527 A MX2017000527 A MX 2017000527A
Authority
MX
Mexico
Prior art keywords
antibody formulations
crystalline antibody
crystalline
formulations
antibody crystals
Prior art date
Application number
MX2017000527A
Other languages
English (en)
Inventor
Khalaf Nazer
MANDAPATI Saraswathi
J Patel Reena
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2017000527A publication Critical patent/MX2017000527A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen en la presente cristales de anticuerpo anti-PCSK9, métodos para elaborar tales cristales de anticuerpo y formulaciones que comprenden los cristales de anticuerpo.
MX2017000527A 2014-07-14 2015-07-13 Formulaciones de anticuerpos cristalinos. MX2017000527A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462024393P 2014-07-14 2014-07-14
PCT/US2015/040217 WO2016010927A1 (en) 2014-07-14 2015-07-13 Crystalline antibody formulations

Publications (1)

Publication Number Publication Date
MX2017000527A true MX2017000527A (es) 2017-08-10

Family

ID=53836192

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000527A MX2017000527A (es) 2014-07-14 2015-07-13 Formulaciones de anticuerpos cristalinos.

Country Status (7)

Country Link
US (2) US20170198059A1 (es)
EP (1) EP3169710A1 (es)
JP (3) JP2017525680A (es)
AU (2) AU2015289874A1 (es)
CA (1) CA2954767A1 (es)
MX (1) MX2017000527A (es)
WO (1) WO2016010927A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015289967A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
EP3169710A1 (en) * 2014-07-14 2017-05-24 Amgen Inc. Crystalline antibody formulations
US20170056504A1 (en) * 2015-09-02 2017-03-02 Kenneth I. Kohn Method of extending half-life of crystaline antibodies
WO2018170098A1 (en) 2017-03-14 2018-09-20 Amgen Inc. Methods directed to crystalline biomolecules
AU2018258676B2 (en) 2017-04-28 2024-09-19 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
US12257343B2 (en) 2017-04-28 2025-03-25 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
BR112020005959A2 (pt) * 2017-09-26 2020-10-06 Biocon Biologics India Limited filtração automatizada integrada para separação, lavagem e secagem de cristais de peptídeos
GB2584687B (en) * 2019-06-11 2023-08-23 Univ Newcastle Crystallisation of chemical molecules

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU698393B2 (en) 1994-06-24 1998-10-29 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US6020004A (en) 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6432449B1 (en) 1998-05-18 2002-08-13 Amgen Inc. Biodegradable sustained-release alginate gels
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
AU2002256971B2 (en) * 2000-12-28 2008-04-03 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US8821086B2 (en) * 2006-12-22 2014-09-02 Tennine Corporation Method and apparatus for controlled-fracture machining
WO2008109871A2 (en) * 2007-03-08 2008-09-12 Irm Llc Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
MX2009010957A (es) * 2007-04-13 2009-10-29 Novartis Ag Moleculas y metodos para modular la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9).
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20130072665A1 (en) * 2007-08-23 2013-03-21 Simon Mark Jackson Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
CA2720681C (en) * 2008-04-23 2016-08-02 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
KR100985090B1 (ko) * 2008-05-23 2010-10-04 한국과학기술연구원 크라이센 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
WO2011028938A1 (en) * 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
IN2012DN03824A (es) * 2009-10-30 2015-08-28 Merck Sharp & Dohme
JO3756B1 (ar) * 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
PL2668212T3 (pl) * 2011-01-28 2018-08-31 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20140004122A1 (en) * 2011-05-10 2014-01-02 Amgen Inc. Methods for treating or preventing cholesterol related disorders
ITPN20110039A1 (it) * 2011-05-24 2012-11-25 Keyline S P A Blocchetto di presa perfezionato per macchina duplicatrice di chiavi
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
EP2849788B1 (en) * 2012-05-17 2018-01-03 Cyon Therapeutics Inc. Proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors for use in treating sepsis and septic shock
WO2013188855A1 (en) * 2012-06-15 2013-12-19 Genentech, Inc. Anti-pcsk9 antibodies, formulations, dosing, and methods of use
US20150335615A1 (en) * 2013-01-04 2015-11-26 Toshihisa Kawai Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation
US20160039945A1 (en) * 2013-03-15 2016-02-11 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
EP3754012A1 (en) * 2013-03-15 2020-12-23 Alder Biopharmaceuticals, Inc. Antibody purification and purity monitoring
WO2014197752A1 (en) * 2013-06-07 2014-12-11 Regeneron Pharmaceuticals, Inc. Methods fo inhibting atherosclerosis by administering an inhibitor of pcsk9
US20150004174A1 (en) * 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
CA2916259C (en) * 2013-06-28 2024-02-20 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
US20150140002A1 (en) * 2013-10-11 2015-05-21 Sanofi Use of a pcsk9 inhibitor to treat hyperlipidemia
TWI670077B (zh) * 2013-11-12 2019-09-01 賽諾菲生物技術公司 使用ｐｃｓｋ９抑制劑之給藥療程
US8883157B1 (en) * 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) * 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) * 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
WO2015123423A2 (en) * 2014-02-14 2015-08-20 Regeneron Pharmaceuticals, Inc Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
KR20160124787A (ko) * 2014-02-21 2016-10-28 메디뮨 엘엘씨 항-pcsk9∼glp-1 융합체 및 사용 방법
JP2017509624A (ja) * 2014-03-17 2017-04-06 サノフィ・バイオテクノロジー 心血管リスクを低減させる方法
WO2015140079A1 (en) * 2014-03-17 2015-09-24 Sanofi Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
EP3169710A1 (en) * 2014-07-14 2017-05-24 Amgen Inc. Crystalline antibody formulations
AU2015289967A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
RU2735521C2 (ru) * 2014-07-16 2020-11-03 Санофи Байотекнолоджи Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh)
EP3197492A1 (en) * 2014-09-23 2017-08-02 Pfizer Inc Treatment with anti-pcsk9 antibodies
EP3834864A1 (en) * 2016-04-08 2021-06-16 Amgen Inc. Drug delivery device, method of manufacture, and method of use
WO2017186928A1 (en) * 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
CA3038909A1 (en) * 2016-09-29 2018-04-05 Amgen Inc. Low-viscosity antigen binding proteins and methods of making them
US11459401B2 (en) * 2016-10-06 2022-10-04 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
JOP20190112A1 (ar) * 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
US20190031774A1 (en) * 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
AU2018350992A1 (en) * 2017-10-18 2020-05-21 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
WO2020014143A1 (en) * 2018-07-08 2020-01-16 Specifica Inc. Antibody libraries with maximized antibody developability characteristics

Also Published As

Publication number Publication date
US20190127485A1 (en) 2019-05-02
US11267902B2 (en) 2022-03-08
JP2018150337A (ja) 2018-09-27
JP2017525680A (ja) 2017-09-07
WO2016010927A1 (en) 2016-01-21
AU2015289874A1 (en) 2017-02-02
EP3169710A1 (en) 2017-05-24
US20170198059A1 (en) 2017-07-13
AU2021201422A1 (en) 2021-03-25
CA2954767A1 (en) 2016-01-21
JP2020172526A (ja) 2020-10-22

Similar Documents

Publication Publication Date Title
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
MY193661A (en) Anti-tim3 antibodies and methods of use
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
EP3104865A4 (en) Micro-organoids, and methods of making and using the same
MY176285A (en) Anti-fcrh5 antibodies
PH12016501763A1 (en) Multispecific antibodies
EP3461845A8 (en) Anti-cd33 antibodies and immunoconjugates
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
MY192927A (en) Fused bicyclic compounds for the treatment of disease
MX2017000527A (es) Formulaciones de anticuerpos cristalinos.
MX369623B (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX2021006003A (es) Formulaciones de anticuerpos cristalinos.
MX2020012893A (es) Formulaciones de proteinas.
EP3515949A4 (en) NEW ANTI-PCSK9 ANTIBODIES
MX2019010640A (es) Formas cristalinas de acido obeticolico.
EP3515950A4 (en) NEW ANTI-PCSK9 ANTIBODIES
MY167350A (en) Fat-and-oil composition and chocolate
MX2016004573A (es) Inhibidores de nsp4 y metodos de uso.
NZ721832A (en) Solid forms of tenofovir
MX2015010789A (es) Anticuerpos anti-pcsm.